Centre de Pathologie - =?iso-8859-1?Q?Bi=E8vres?= <bievres6@club-internet.fr>
Reply-To:
Content-Type:
text/html; charset=us-ascii
<!doctype html public "-//w3c//dtd html 4.0 transitional//en">
<html>
"<font size=+2>Variability of Her-2/neu Detection in Archival Breast Carcinoma
using Clones CB-11, A0485, TAB250 and 3B5 and Different Grading Schemes</font>."
<br>H.Yee PhD, MD; D. Chhieng MD*, L. Chiriboga PhD; A.E. Doniguian MD^
<br>New York University School of Medicine, NY, NY; *University of Alabama,
Birmingham, AL; ^ St. Joseph's Hospital and Medical Center, Patterson NJ
<center>
<p>ABSTRACT</center>
BACKGROUND:
<br>Overexpression of Her-2/neu has been correlated with poor prognosis
in lymph node positive and negative breast cancer. Overexpression
of Her-2/neu is therapeutically important for patients for whom HERCEPTIN
(trastuzumab) is being considered. The detection of this protein
by immunohistochemistry of archival tissue is the preferred method; however,
there is controversy regarding the sensitivity and specificity of commercially
available antibodies against HER-2/neu and criteria for positive staining.
<br>DESIGN:
<br>271 archival breast cancers from 1998-99 were studied (150 from NYU/Bellevue
Hospital, 82 from University of Alabama, Birmingham, 39 From St. Joseph's
Hospital and Medical Center). All tissue blocks were stained with four
commercially available antibodies, CB-11, AO485, TAB250 and 3B5.
The staining was performed on an automated immunostainer according to the
antibody manufacturer protocols. Staining was evaluated according
to 3 grading systems; an established graded scale (Hercep Test), a CALGB
standard (50% postive staining) and a 10% staining cutoff. Only membrane
staining was regard as positive.
<br>RESULTS:
<br>Overall, 20-35% of all cases stained positive for any clone. Using
a graded scale (Hercep Test), CALGB scale and 10% cutoff scale respectively,
the individual clones yielded the following:
<br>
A0485
CB11
TAB250
3B5
<br>"Graded"
25%
29 %
23%
26%
<br>CALGB
22%
25%
23%
20%
<br>10%
31%
25%
28%
30%
<p>CONCLUSIONS:
<br>There is greater variability in the percentage of "positive" staining
using various grading criteria; however, there is less variability
within each group for each antibody. We conclude that the variability
of the percentage of positive Her-2/neu staining is influenced more by
the choice of grading scheme rather than the type of antibody used.
<br>
<p>Centre de Pathologie - Bièvres wrote:
<blockquote TYPE=CITE>Dear Luis,
<p>Could you summarize on the HistoNet the findings reported in your poster
?
<p>Thanks in advance
<p>Andre
<p>Andre Balaton
<br>Centre de Pathologie
<br>Bievres
<br>France
<p>" Date: 30 May 2000 12:41:08 -0500
<br>From: Luis Chiriboga <luis.chiriboga@med.nyu.edu>
<br>Subject: Re: Her-2-Neu
<p>Use the ventana her-2-neu (CB11) with a 10 minute 0.01M pH6.0 citrate
<br>microwave, 32 minute incubation on the nexus stainer.
<br>Use the zymed her-2-neu (TAB250) 1:20 overnight on the nexus stainer.
NOt
<br>sure if this is the V-line antibody.
<br>recently did a comparison among erb antibodies. abstract presented
at CAP
<br>meeting.
<br>Titled "Variability of Her-2/neu detection in archival breast carcinoma
<br>using
<br>clones CB11, AO485, TAB250 and 3B5 and different grading schemes"
<p>Jerry Santiago wrote:
<p>> We are doing a comparison study with Her-2-Neu, and I will like to
know if
<br>anybody have experience with the V-Line Her-2-Neu from Zymed,
and/or the
<br>Ventana Ready Her-2-Neu?
<br>>
<br>> Thanks
<p>- --
<br>Luis Chiriboga Ph.D HT(ASCP)QIHC
<br>Department of Pathology 4W27
<br>Bellevue Hospital
<br>NYU School of Medicine
<br>First Avenue & 27th Street
<br>New York, NY 10016
<br>(212)562-4667
<br>"
<p>----------------------------------------------------------------------</blockquote>
<p>--
<br>Luis Chiriboga Ph.D HT(ASCP)QIHC
<br>Department of Pathology 4W27
<br>Bellevue Hospital
<br>NYU School of Medicine
<br>First Avenue & 27th Street
<br>New York, NY 10016
<br>(212)562-4667
<br> </html>